logo
logo
Sign in

The global Inflammatory Bowel Disease Market Growth Accelerated by increased Diagnosis and Treatment

avatar
Niranjan Mardakar
The global Inflammatory Bowel Disease Market Growth Accelerated by increased Diagnosis and Treatment

Inflammatory Bowel Disease products such as mesalamine, glucocorticosteroids, and biological therapies are used for the treatment of ulcerative colitis and Crohn's disease conditions. These products provide relief from symptoms such as abdominal pain, diarrhea, rectal bleeding etc. associated with inflammatory bowel diseases.

The global Inflammatory Bowel Disease Market is estimated to be valued at US$ 2,309.43 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increased diagnosis and treatment of inflammatory bowel diseases has accelerated the growth of this market. Early diagnosis through improved awareness and screening programs has helped people receive timely treatment for conditions like ulcerative colitis and Crohn's disease. This has further driven the demand for mesalamine, corticosteroids and biological therapy drugs in the inflammatory bowel disease market. Research is also ongoing to develop new and improved drugs with lesser side effects to manage symptoms of these chronic conditions more effectively over long term.

Segment Analysis

The Global Inflammatory Bowel Disease Market Size is dominated by the ulcerative colitis segment. Ulcerative colitis accounts for nearly 60% of the total market share as it is the most common type of inflammatory bowel disease. It causes long-lasting inflammation and ulcers in the top layer of the lining of the large intestine and rectum.

Key Takeaways

The global Inflammatory Bowel Disease Market is estimated to be valued at US$ 2,309.43 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024-2031.


Regional analysis: North America region dominates the global inflammatory bowel disease market and is expected to continue its dominance during the forecast period. The high prevalence of inflammatory bowel disease and rising healthcare expenditure in the US drive market growth in this region.

Key players: Key players operating in the inflammatory bowel disease market are Pfizer Inc., Johnson and Johnson Services, Inc., Merck KGaA, Actavis Pharma, Inc., Apotex Inc. Pfizer Inc. is one of the leading players offering a wide range of drugs for treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Johnson and Johnson Services, Inc. is another prominent player with its blockbuster drug REMICADE for the treatment of inflammatory bowel diseases.

Get More Insights On This Topic: https://www.pressreleasebulletin.com/inflammatory-bowel-disease-market-size-share-analysis-2023-2030/

collect
0
avatar
Niranjan Mardakar
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more